CDC73 mutations and parafibromin immunohistochemistry in parathyroid tumors: Clinical correlations in a single-centre patient cohort

Cellular Oncology

Volumn 35, Issue 6, 2012, Pages 411-422

  Guarnieri, Vito ^a   Battista, Claudia ^a   Muscarella, Lucia Anna ^a   Bisceglia, Michele ^a   De Martino, Danilo ^a   Baorda, Filomena ^a   Maiello, Evaristo ^a   D'Agruma, Leonardo ^a   Chiodini, Iacopo ^b   Clemente, Celeste ^a   Minisola, Salvatore ^b   Romagnoli, Elisabetta ^c   Corbetta, Sabrina ^c   Viti, Raffaella ^a   Eller Vainicher, Cristina ^b   Spada, Anna ^b   Iacobellis, Michela ^f   Malavolta, Nazzarena ^g   Carella, Massimo ^a   Canaff, Lucie ^d,e   Hendy, Geoffrey N ^d,e   Cole, David E C ^h   Scillitani, Alfredo ^a   more..

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d MCGILL UNIVERSITY   (Canada)

^e ROYAL VICTORIA HOSPITAL   (Canada)

^f MIULLI GENERAL HOSPITAL   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF TORONTO   (Canada)

Author keywords

Atypical adenoma; CDC73; HRPT2; Parafibromin; Parathyroid tumours

Indexed keywords

CALCIUM SENSING RECEPTOR; CDC73 PROTEIN, HUMAN; TUMOR SUPPRESSOR PROTEIN;

ADULT; AGED; ANALYTIC METHOD; ARTICLE; BRAIN METASTASIS; CALCIUM BLOOD LEVEL; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CDC73 GENE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; EXON; FEMALE; FOLLOW UP; FRAMESHIFT MUTATION; GENE; GENE MUTATION; HUMAN; LUNG METASTASIS; MALE; MIDDLE AGED; NONSENSE MUTATION; PARAFIBROMIN IMMUNOHISTOCHEMISTRY; PARATHYROID ADENOMA; PARATHYROID ATYPICAL ADENOMA; PARATHYROID CARCINOMA; PARATHYROID TYPICAL ADENOMA; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SOMATIC MUTATION; TUMOR VOLUME; ADENOMA; CARCINOMA; COHORT ANALYSIS; GENETICS; IMMUNOHISTOCHEMISTRY; METABOLISM; MUTATION; PARATHYROID TUMOR; PATHOLOGY; PEDIGREE; POLYMERASE CHAIN REACTION; VERY ELDERLY;

ADENOMA; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; COHORT STUDIES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MUTATION; PARATHYROID NEOPLASMS; PEDIGREE; POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT;

EID: 84878168394     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-012-0100-x     Document Type: Article

References (36)

1. S.J. Marx, Hyperparathyroid and hypoparathyroid disorders. N. Engl. J. Med. 343, 1863-1865 (2000)
2. J.M. Sharretts, W.F. Simonds, Clinical and molecular genetics of parathyroid neoplasms. Best Pract. Res. Clin. Endocrinol. Metab. 24, 491-502 (2010)
3. C. Marcocci, F. Cetani, M.R. Rubin, S.J. Silverberg, A. Pinchera, J.P. Bilezikian, Parathyroid carcinoma. J. Bone Miner. Res. 23, 1869-1880 (2008)
4. J.M. Sharretts, E. Kebebew, W.F. Simonds, Parathyroid cancer. Semin. Oncol. 37, 580-590 (2010)
5. B. Schantz, B. Castleman, Parathyroid carcinoma. A study of 70 cases. Cancer 31, 600-605 (1973)
6. L. Bondeson, L. Grimelius, R.A. DeLellis, R. Lloyd, G. Akerstrom, C. Larsson, A. Arnold, C. Eng, E. Shane, J.P. Bilezikian, Parathyroid carcinoma, in Pathology and genetics of tumours of endocrine organs. WHO classification of tumours, ed. by R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng (IARC Press, Lyon, 2004), pp. 124-127
7. R.A. DeLellis, Challenging lesions in the differential diagnosis of endocrine tumors: Parathyroid carcinoma. Endocr. Pathol. 19, 221-225 (2008)
8. J.D. Carpten, C.M. Robbins, A. Villablanca, L. Forsberg, S. Presciuttini, J. Bailey-Wilson, W.F. Simonds, E.M. Gillanders, A.M. Kennedy, J.D. Chen, S.K. Agarwal, R. Sood, M.P. Jones, T.Y. Moses, C. Haven, D. Petillo, P.D. Leotlela, B. Harding, D. Cameron, A.A. Pannett, A. Höög, H. Heath 3rd, L.A. James-Newton, B. Robinson, R.J. Zarbo, B.M. Cavaco, W. Wassif, N.D. Perrier, I.B. Rosen, U. Kristoffersson, P.D. Turnpenny, L.O. Farnebo, G.M. Besser, C.E. Jackson, H. Morreau, J.M. Trent, R.V. Thakker, S.J. Marx, B.T. Teh, C. Larsson, M.R. Hobbs, HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome. Nat. Genet. 32, 676-680 (2002)
9. P.J. Newey, M.R. Bowl, T. Cranston, R.V. Thakker, Cell division cycle protein 73 homolog (CDC73) mutations in the hyperparathyroidism-jaw tumor syndrome (HPT-JT) and parathyroid tumors. Hum. Mutat. 31, 295-307 (2010)
10. T.M. Shattuck, S. Valimäki, T. Obara, R.D. Gaz, O.H. Clark, D. Shoback, M.E. Wierman, K. Tojo, C.M. Robbins, J.D. Carpten, L.O. Farnebo, C. Larsson, A. Arnold, Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma. N. Engl. J. Med. 349, 1722-1729 (2003)
11. C.C. Juhlin, A. Villablanca, K. Sandelin, F. Haglund, J. Nordenstrom, L. Forsberg, L. Branstrom, T. Obara, A. Arnold, C. Larsson, A. Höög, Parafibromin immunoreactivity: Its use as an additional diagnostic marker for parathyroid tumor classification. Endocr. Relat. Cancer 14, 501-512 (2007)
12. F. Cetani, E. Ambrogini, P. Viacava, E. Pardi, G. Fanelli, A.G. Naccarato, S. Borsari, M. Lemmi, P. Berti, P. Miccoli, A. Pinchera, C. Marcocci, Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma? Eur. J. Endocrinol. 156, 547-554 (2007)
13. V.M. Howell, C.J. Haven, K. Kahnoski, S.K. Khoo, D. Petillo, J. Chen, G.J. Fleuren, B.G. Robinson, L.W. Delbridge, J. Philips, A.E. Nelson, U. Krause, K. Hammje, H. Dralle, C. Hoang-Vu, O. Gimm, D.J. Marsh, H. Morreau, B.T. Teh, HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours. J. Med. Genet. 40, 657-663 (2003)
14. V.M. Howell, A. Gill, A. Clarkson, A.E. Nelson, R. Dunne, L.W. Delbridge, B.G. Robinson, B.T. Teh, O. Gimm, D.J. Marsh, Accuracy of combined protein gene product 9.5 and parafibromin markers for immunohistochemical diagnosis of parathyroid carcinoma. J. Clin. Endocrinol. Metab. 94, 434-441 (2009)
15. L.J. Krebs, T.M. Shattuck, A. Arnold, HRPT2 mutational analysis of typical sporadic parathyroid adenomas. J. Clin. Endocrinol. Metab. 90, 5505-5507 (2005)
16. F. Cetani, E. Pardi, S. Borsari, P. Viacava, G. Dipollina, L. Cianferotti, E. Ambrogini, E. Gazzerro, G. Colussi, P. Berti, P. Miccoli, A. Pinchera, C. Marcocci, Genetic analysis of the HRPT2 gene in primary hyperparathyroidism: Germline and somatic mutations in familial and sporadic parathyroid tumors. J. Clin. Endocrinol. Metab. 89, 5583-5591 (2004)
17. M.H. Tan, C. Morrison, P. Wang, X. Yang, C.J. Haven, C. Zhang, P. Zhao, M.S. Tretiakova, E. Korpi-Hyovalti, J.R. Burgess, K.C. Soo, W.K. Cheah, B. Cao, J. Resau, H. Morreau, B.T. Teh, Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma. Clin. Cancer Res. 10, 6629-6637 (2004)
18. A.J. Gill, A. Clarkson, O. Gimm, J. Keil, H. Dralle, V.M. Howell, D.J. Marsh, Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism-jaw tumor (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias. Am. J. Surg. Pathol. 30, 1140-1149 (2006)
19. C.C. Juhlin, I.-L. Nilsson, K. Johansson, F. Haglund, A. Villablanca, A. Höög, C. Larsson, Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas. Endocr. Pathol. 21, 166-177 (2010)
20. S. Mangray, K.C. Kurek, E. Sabo, R.A. DeLellis, Immunohistochemical expression of parafibromin is of limited value in distinguishing parathyroid carcinoma from adenoma. Mod. Pathol. 21, 108A (2008). abstract
21. G.G. Fernandez-Ranvier, E. Khanafshar, D. Tacha, M. Wong, E. Kebebew, Q.Y. Duh, O.H. Clark, Defining a molecular phenotype for benign and malignant parathyroid tumors. Cancer 115, 334-344 (2009)
22. C.C. Juhlin, C. Larsson, T. Yakoleva, I. Leibiger, B. Leibiger, A. Alimov, G. Weber, A. Hoog, A. Villablanca, Loss of parafibromin expression in a subset of parathyroid adenomas. Endocr. Relat. Cancer 13, 509-523 (2006)
23. C.J. Haven, M. van Puijenbroek, M.H. Tan, B.T. Teh, G.J. Fleuren, T. van Wezel, H. Morreau, Identification of MEN1 and HRPT2 somatic mutations in paraffin-embedded (sporadic) parathyroid carcinomas. Clin. Endocrinol. 67, 370-376 (2007)
24. V. Guarnieri, L. Canaff, F.H.J. Yun, A. Scillitani, C. Battista, L.A. Muscarella, B.Y.L. Wong, A. Notarangelo, L. D'Agruma, M. Sacco, D.E.C. Cole, G.N. Hendy, Calcium-sensing receptor (CASR) mutations in hypercalcemic states: Studies from a single endocrine clinic over three years. J. Clin. Endocrinol. Metab. 95, 1819-1829 (2010)
25. V. Guarnieri, A. Scillitani, L.A. Muscarella, C. Battista, N. Bonfitto, M. Bisceglia, S. Minisola, M.L. Mascia, L. D'Agruma, D.E.C. Cole, Diagnosis of parathyroid tumors in familial isolated hyperparathyroidism with HRPT2 mutation: Implications for cancer surveillance. J. Clin. Endocrinol. Metab. 91, 2827-2832 (2006)
26. V. Guarnieri, M. Bisceglia, N. Bonfitto, F. Cetani, C. Marcocci, S. Minisola, C. Battista, I. Chiodini, D.E.C. Cole, A. Scillitani, Re: Familial hyperparathyroidism: Surgical outcome after 30 years of follow-up in three families with germline HRPT2 mutations. Surgery 144, 839-840 (2008)
27. L. Grimelius, R.A. DeLellis, L. Bondeson, G. Akerstrom, A. Arnold, K.O. Frinssila, G.N. Hendy, D. Dupuy, C. Eng, Parathyroid adenoma, in Pathology and genetics of tumours of endocrine organs. WHO classification of tumours, ed. by R.A. DeLellis, R.V. Lloyd, P.U. Heitz, C. Eng (IARC Press, Lyon, 2004), pp. 128-132
28. P. Parrella, D. Sidransky, S.L. Merbs, Allelotype of posterior uveal melanoma: Implications for a bifurcated tumor progression pathway. Cancer Res. 59, 3032-3037 (1999)
29. G. Masi, L. Barzon, M. Iacobone, G. Viel, A. Porzionato, V. Macchi, R. De Caro, G. Favia, G. Palù, Clinical, genetic, and histopathologic investigation of CDC73-related familial hyperparathyroidism. Endocr. Relat. Cancer 15, 1115-1126 (2008)
30. R.I. Skotheim, C.B. Diep, S.M. Kraggerud, K.S. Jakobsen, R.A. Lothe, Evaluation of loss of heterozygosity/allelic imbalance scoring in tumor DNA. Cancer Genet. Cytogenet. 127, 64-70 (2001)
31. K. Sandelin, O. Tullgren, L.O. Farnebo, Clinical course of metastatic parathyroid cancer. World J. Surg. 18, 594-599 (1994)
32. R. Domingues, R.A. Tomaz, C. Martins, C. Nunes, M.J. Bugalho, B.M. Cavaco, Identification of the first germline HRPT2 wholegene deletion in a patient with primary hyperparathyroidism. Clin. Endocrinol. 76, 33-38 (2012)
33. C.D. Greenman, Haploinsufficient gene selection in cancer. Science 337, 47-48 (2012)
34. T.G. Kelly, T.M. Shattuck, M. Reyes-Mugica, A.F. Stewart, W.F. Simonds, R. Udelsman, A. Arnold, T.O. Carpenter, Surveillance for early detection of aggressive parathyroid disease: Carcinoma and atypical adenoma in familial isolated hyperparathyroidism associated with a germline HRPT2 mutation. J. Bone Miner. Res. 21, 1666-1671 (2006)
35. C.C. Juhlin, F. Haglund, T. Obara, A. Arnold, C. Larsson, A. Höög, Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours. Virchows Arch. 459, 47-53 (2011)
36. V.M. Howell, J.W. Cardinal, A.L. Richardson, O. Gimm, B.G. Robinson, D.J. Marsh, Rapid mutation screening for HRPT2 and MEN1 mutations associated with familial and sporadic primary hyperparathyroidism. J. Mol. Diagn. 8, 559-566 (2006)